Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Shandong Sinobioway Biomedicine Co., Ltd. specializes in the development and production of biopharmaceuticals, particularly in the fields of immunology and oncology. The company operates primarily in China, leveraging its proprietary technologies to create a diverse product portfolio that includes monoclonal antibodies and recombinant proteins, which are critical for treating various diseases.
Shandong Sinobioway generates revenue primarily through the sale of biopharmaceutical products, which are priced based on their therapeutic value and competitive positioning in the market. The company benefits from a strong R&D pipeline, allowing it to introduce innovative products that command premium pricing. Its low debt levels (Debt/Equity of 0.02) provide financial flexibility to invest in growth initiatives.
Regulatory approvals for new drugs
Partnerships with larger pharmaceutical companies
Market demand for biopharmaceuticals in China
Changes in healthcare policies affecting drug pricing
Technological disruption in biopharmaceuticals
Regulatory changes impacting drug approval processes
Emergence of generic alternatives to its proprietary drugs
Increased competition from domestic and international biopharmaceutical firms
Negative operating cash flow impacting liquidity
Potential future capital needs for R&D funding
moderate - The company's performance is somewhat tied to the overall healthcare spending trends, which can be influenced by economic cycles.
Low - The company has minimal debt, so rising interest rates do not significantly impact its financing costs or operational decisions.
minimal - The company operates with a very low debt level, reducing its reliance on credit markets.
growth - Investors looking for exposure to the biopharmaceutical sector with potential for high returns from innovative products.
high - The stock has shown significant price fluctuations, evidenced by a 1-year return of -59.5%.
